Duchenne News Tags: Avidity Biosciences

On January 22, 2026, Avidity Bioscience shared a Managed Access Program (MAP) – Frequently Asked Questions sheet with the Duchenne community to provide clarity and address the most frequently asked...

On November 20, 2025, Avidity Biosciences shared a Community Letter detailing their definitive merger acquisition by Novartis. This letter comes after the official announcement on October 26, 2025.  To view...

On November 19, 2025, Avidity Biosciences, Inc. announced its Managed Access Program (MAP) for investigational therapy delpacibart zotadirsen (del-zota) for eligible people with Duchenne muscular dystrophy mutations amenable to exon...

On October 26, 2025, Avidity Biosciences, Inc. announced that it has entered into a definitive merger agreement with Novartis AG (“Novartis”) which has been unanimously approved by the Boards of...

On July 23, 2025, Avidity Biosciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to delpacibart zotadirsen (del-zota) for the treatment of Duchenne...

On June 9, 2025, Avidity Biosciences, Inc. announced positive topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE™ program in Facioscapulohumeral Muscular Dystrophy (FSHD)....

On June 9, Avidity Biosciences Inc. announced the accelerated approval regulatory pathway in the United States is open for delpacibart braxlosiran (del-brax) in the treatment of facioscapulohumeral muscular dystrophy (FSHD). Additionally, the...

On March 17, 2025, Avidity Biosciences, Inc. announced positive del-zota topline data from the Phase 1/2 EXPLORE44® trial in people living with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44)...

On February 27, 2025, Avidity Biosciences  reported financial results for the fourth quarter ended December 31, 2024, highlighting recent progress and reiterating 2025 catalysts for its three clinical programs. To view...

Avidity Biosciences announces its progress and planning for a transformational year in 2025.

Avidity shares updates on EXPLORE44 trial in a community letter and press release.

Avidity shares an update on positive AOC 1044 data in healthy volunteers from the Phase 1/2 EXPLORE44™ clinical trial.

Avidity announces positive topline data from the Phase 1/2 MARINA™ clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1